MX2011013061A - Formulaciones oftalmicas de fluticasona y metodos de uso. - Google Patents

Formulaciones oftalmicas de fluticasona y metodos de uso.

Info

Publication number
MX2011013061A
MX2011013061A MX2011013061A MX2011013061A MX2011013061A MX 2011013061 A MX2011013061 A MX 2011013061A MX 2011013061 A MX2011013061 A MX 2011013061A MX 2011013061 A MX2011013061 A MX 2011013061A MX 2011013061 A MX2011013061 A MX 2011013061A
Authority
MX
Mexico
Prior art keywords
fluticasone
allergic conjunctivitis
methods
ophthalmic formulations
eye
Prior art date
Application number
MX2011013061A
Other languages
English (en)
Inventor
George Minno
Matthew Jonathan Chapin
Mark Barry Abelson
Paul Gomes
Jackie Nice
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of MX2011013061A publication Critical patent/MX2011013061A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

La presente invención proporciona formulaciones oftálmicas de fluticasona que ofrecen una formulación cómoda cuando se pone gota a gota en el ojo y es efectiva en el tratamiento de conjuntivitis alérgica y/o blenoftalmia alérgica. La invención además proporciona métodos para tratar la conjuntivitis alérgica y/o blenoftalmia alérgica en un individuo en necesidad de tal tratamiento por aplicación tópica de las formulaciones de fluticasona de la invención directamente al ojo.
MX2011013061A 2009-06-05 2010-06-04 Formulaciones oftalmicas de fluticasona y metodos de uso. MX2011013061A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18448409P 2009-06-05 2009-06-05
PCT/US2010/037426 WO2010141834A1 (en) 2009-06-05 2010-06-04 Ophthalmic formulations of fluticasone and methods of use

Publications (1)

Publication Number Publication Date
MX2011013061A true MX2011013061A (es) 2012-02-28

Family

ID=43298182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013061A MX2011013061A (es) 2009-06-05 2010-06-04 Formulaciones oftalmicas de fluticasona y metodos de uso.

Country Status (6)

Country Link
US (1) US20110105450A1 (es)
EP (1) EP2437743A4 (es)
JP (1) JP2012528889A (es)
CA (1) CA2764473A1 (es)
MX (1) MX2011013061A (es)
WO (1) WO2010141834A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072809A1 (en) 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
WO2006127945A1 (en) 2005-05-26 2006-11-30 Neuron Systems Compositions and methods of treating retinal disease
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
AU2012291841A1 (en) * 2011-08-02 2014-02-06 Cipla Limited Pharmaceutical composition comprising ebastine and fluticasone
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
FR3019465B1 (fr) 2014-04-02 2017-06-23 Horus Pharma Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US9981041B2 (en) 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
HUE053233T2 (hu) 2017-10-16 2021-06-28 Faes Farma Sa Bilasztint és mometanzont tartalmazó vizes készítmények
WO2020018498A1 (en) * 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
JP2022502499A (ja) 2018-09-25 2022-01-11 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
US20210379081A1 (en) 2018-10-24 2021-12-09 Ferring B.V. Mucoadhesive pharmaceutical compositions of corticosteroids
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
KR20220038443A (ko) 2019-07-23 2022-03-28 니콕스 오프탈믹스,아이엔씨. 무균 안과용 수성 플루티카손 프로피오네이트 a형 나노결정 현탁액을 제조하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
EP3943069A1 (en) * 2009-03-17 2022-01-26 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use

Also Published As

Publication number Publication date
JP2012528889A (ja) 2012-11-15
CA2764473A1 (en) 2010-12-09
EP2437743A1 (en) 2012-04-11
WO2010141834A1 (en) 2010-12-09
US20110105450A1 (en) 2011-05-05
EP2437743A4 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
MX2011013061A (es) Formulaciones oftalmicas de fluticasona y metodos de uso.
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2012DN00624A (es)
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
IN2015MN00478A (es)
MX2012006881A (es) Composiciones de povidona-yodo oftalmicas no irritantes.
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EP2328550A4 (en) MUCOADHERENT COMPOSITIONS AND THEIR USE
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EP2588096A4 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF CONTACT LENS-RELATED PAPILLAR TIN TREATMENT AND ALLERGIC EYE DISEASES
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
BR112012015386B8 (pt) composição oftálmica tópica
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
IN2014DN10404A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal